Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Wiener klinisches Magazin
Erschienen in:

01.04.2016 | Genetik

Ein vielversprechendes Werkzeug

Therapiesteuerung anhand zellfreier, zirkulierender Tumor-DNA

verfasst von: Ass.-Prof. Priv.-Doz. Mag. Dr. Ellen Heitzer

Erschienen in: Wiener klinisches Magazin | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Zusammenfassung

Durch die zunehmende Anzahl an zielgerichteten Therapien kommt es in der Behandlung von Krebserkrankungen zu einem Paradigmenwechsel. Die molekulargenetische Diagnostik und kontinuierliche Charakterisierung der Tumore gewinnt daher zunehmend an Bedeutung. In den meisten Fällen sind aber wiederholte Gewebsentnahmen eines Tumors und dessen Metastasen nicht durchführbar, weshalb eine Analyse von tumorspezifischen Veränderungen aus Blut bzw. Plasma oder Serum vorteilhaft wäre. Wiederholte Blutabnahmen sind einfach, schnell und kostengünstig zu bewerkstelligen, ohne den Patienten zu belasten. Zellfreie, zirkulierende DNA-Fragmente (ctDNA), welche von unterschiedlichen Tumorlokalisationen in die Zirkulation entlassen werden, reflektieren die Veränderungen im Tumorgenom in Echtzeit und erlauben somit eine Überwachung während des gesamten Therapieverlaufs und darüber hinaus. Unzählige Studien haben die klinische Relevanz von ctDNA als diagnostischen, prädiktiven und prognostischen Biomarker belegt. In dieser Übersichtsarbeit werden die Biologie, methodische Ansätze sowie das Potenzial der ctDNA zu Überwachung des Therapieansprechens diskutiert.
Vorheriger Artikel Panorama
Nächster Artikel Management des multiplen Myeloms
Literatur
1.
Alizadeh AA, Aranda V, Bardelli A, Blanpain C, Bock C, Borowski C et al (2015) Toward understanding and exploiting tumor heterogeneity. Nat Med 21:846–853CrossRefPubMed
2.
Gerlinger M (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:883–892CrossRefPubMed
3.
4.
McGranahan N, Swanton C (2015) Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell 27:15–26CrossRefPubMed
5.
6.
Mandel P, Metais P (1948) Les acides nucleiques du plasma sanguin chez l’homme. C R Seances Soc Biol Fil 142:241–243PubMed
7.
Leon SA, Ehrlich GE, Shapiro B, Labbate VA (1977) Free DNA in the serum of rheumatoid arthritis patients. J Rheumatol 4:139–143PubMed
8.
Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C, Beljanski M (1989) Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology 46:318–322CrossRefPubMed
9.
Heitzer E, Ulz P, Geigl JB (2015) Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem 61:112–123CrossRefPubMed
10.
Stroun M, Lyautey J, Lederrey C, Olson-Sand A, Anker P (2001) About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin Chim Acta 313:139–142CrossRefPubMed
11.
Jahr S (2001) DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61:1659–1665PubMed
12.
Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S et al (2005) Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA 102:16368–16373CrossRefPubMedPubMedCentral
13.
Sikora K, Bedin C, Vicentini C, Malpeli G, D’Angelo E, Sperandio N et al (2015) Evaluation of cell-free DNA as a biomarker for pancreatic malignancies. Int J Biol Markers 30:e136–e141CrossRefPubMed
14.
15.
16.
Heitzer E, Auer M, Hoffmann EM, Pichler M, Gasch C, Ulz P et al (2013) Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer. Int J Cancer J Int Du Cancer 133:346–356CrossRef
17.
Garcia-Olmo DC, Garcia-Olmo D (2013) Biological role of cell-free nucleic acids in cancer: the theory of genometastasis. Crit Rev Oncog 18:153–161CrossRefPubMed
18.
Garcia-Olmo D, Garcia-Olmo DC, Dominguez-Berzosa C, Guadalajara H, Vega L, Garcia-Arranz M (2012) Oncogenic transformation induced by cell-free nucleic acids circulating in plasma (genometastasis) remains after the surgical resection of the primary tumor: A pilot study. Expert Opin Biol Ther 12(Suppl 1):S61–S68CrossRefPubMed
19.
Snyder MW, Kircher M, Hill AJ, Daza RM, Shendure J (2016) Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell 164:57–68CrossRefPubMed
20.
Sun K, Jiang P, Chan KC, Wong J, Cheng YK, Liang RH et al (2015) Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. Proc Natl Acad Sci USA 112:E5503–E5512CrossRefPubMedPubMedCentral
21.
Lo YM, Chan KC, Sun H, Chen EZ, Jiang P, Lun FM et al (2010) Maternal plasma DNA sequencing reveals the genome-wide genetic and mutational profile of the fetus. Sci Transl Med 2:61ra91PubMed
22.
23.
24.
Spindler KL, Pallisgaard N, Vogelius I, Jakobsen A (2012) Quantitative cell-free DNA, kras, and braf mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin Cancer Res 18:1177–1185CrossRefPubMed
25.
Taly V, Pekin D, Benhaim L, Kotsopoulos SK, Le Corre D, Li X et al (2013) Multiplex picodroplet digital pcr to detect kras mutations in circulating DNA from the plasma of colorectal cancer patients. Clin Chem 59:1722–1731CrossRefPubMed
26.
27.
Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DW, Kaper F et al (2012) Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 4:136ra68PubMed
28.
Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA et al (2014) An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 20(5):548–554CrossRefPubMedPubMedCentral
29.
Leary RJ, Sausen M, Kinde I, Papadopoulos N, Carpten JD, Craig D et al (2012) Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med 4:162ra54
30.
Chan KC (2013) Cancer genome scanning in plasma: Detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin Chem 59:211–224CrossRefPubMed
31.
Heitzer E, Auer M, Gasch C, Pichler M, Ulz P, Hoffmann EM et al (2013) Complex tumor genomes inferred from single circulating tumor cells by array-cgh and next-generation sequencing. Cancer Res 73:2965–2975CrossRefPubMed
32.
Heitzer E, Ulz P, Belic J, Gutschi S, Quehenberger F, Fischereder K et al (2013) Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. Genome Med 5:30CrossRefPubMedPubMedCentral
33.
Belic J, Koch M, Ulz P, Auer M, Gerhalter T, Mohan S et al (2015) Rapid identification of plasma DNA samples with increased ctdna levels by a modified fast-seqs approach. Clin Chem 61:838–849CrossRefPubMed
34.
Sozzi G, Conte D, Leon M, Ciricione R, Roz L, Ratcliffe C et al (2003) Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol 21:3902–3908CrossRefPubMed
35.
Sozzi G, Conte D, Mariani L, Lo Vullo S, Roz L, Lombardo C et al (2001) Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res 61:4675–4678PubMed
36.
Chen X, Bonnefoi H, Diebold-Berger S, Lyautey J, Lederrey C, Faltin-Traub E et al (1999) Detecting tumor-related alterations in plasma or serum DNA of patients diagnosed with breast cancer. Clin Cancer Res 5:2297–2303PubMed
37.
Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N et al (2014) Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 6:224ra24CrossRefPubMedPubMedCentral
38.
Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF et al (2013) Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 368:1199–1209CrossRefPubMed
39.
Olsson E, Winter C, George A, Chen Y, Howlin J, Tang MH et al (2015) Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. EMBO Mol Med 7:1034–1047CrossRefPubMedPubMedCentral
40.
Sorensen BS, Wu L, Wei W, Tsai J, Weber B, Nexo E, Meldgaard P (2014) Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib. Cancer 120:3896–3901CrossRefPubMedPubMedCentral
41.
Jiang T, Ren S, Zhou C (2015) Role of circulating-tumor DNA analysis in non-small cell lung cancer. Lung Cancer 90:128–134CrossRefPubMed
42.
Oxnard GR, Paweletz CP, Kuang Y, Mach SL, O’Connell A, Messineo MM et al (2014) Noninvasive detection of response and resistance in egfr-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res 20:1698–1705CrossRefPubMedPubMedCentral
43.
Qiu M, Wang J, Xu Y, Ding X, Li M, Jiang F et al (2015) Circulating tumor DNA is effective for the detection of egfr mutation in non-small cell lung cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev A Publ Am Assoc Cancer Res 24:206–212 (cosponsored by the American Society of Preventive Oncology)CrossRef
44.
Diaz LA Jr (2012) The molecular evolution of acquired resistance to targeted egfr blockade in colorectal cancers. Nature 486:537–540PubMedPubMedCentral
45.
Mohan S, Heitzer E, Ulz P, Lafer I, Lax S, Auer M et al (2014) Changes in colorectal carcinoma genomes under anti-egfr therapy identified by whole-genome plasma DNA sequencing. PLoS Genet 10:e1004271CrossRefPubMedPubMedCentral
46.
Heitzer E, Ulz P, Geigl JB, Speicher MR (2015) Non-invasive detection of genome-wide somatic copy number alterations by liquid biopsies. Mol Oncol. doi:10.1007/s00740-016-0099-0PubMed
47.
Tie J, Kinde I, Wang Y, Wong HL, Roebert J, Christie M et al (2015) Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann Oncol 26:1715–1722CrossRefPubMed
48.
Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, Piskorz AM et al (2013) Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497:108–112CrossRefPubMed
49.
Heidary M, Auer M, Ulz P, Heitzer E, Petru E, Gasch C et al (2014) The dynamic range of circulating tumor DNA in metastatic breast cancer. Breast Cancer Res 16:421CrossRefPubMedPubMedCentral
Metadaten
Titel
Ein vielversprechendes Werkzeug
Therapiesteuerung anhand zellfreier, zirkulierender Tumor-DNA
verfasst von
Ass.-Prof. Priv.-Doz. Mag. Dr. Ellen Heitzer
Publikationsdatum
01.04.2016
Verlag
Springer Vienna
Erschienen in
Wiener klinisches Magazin / Ausgabe 2/2016
Print ISSN: 1869-1757
Elektronische ISSN: 1613-7817
DOI
https://doi.org/10.1007/s00740-016-0099-0

Weitere Artikel der Ausgabe 2/2016

Die Nähe von Schönheit und Grauen

  • Editorial

Neue Option für Erstlinienbehandlung

  • aktuell

Radiologie im Zentrum

  • aktuell

Das komplett künstliche Herz

  • Open Access
  • Herzchirurgie

Panorama

  • Panorama

Fortgeschrittenes NSCLC

  • aktuell